Mutant fragments of OspA and methods and uses relating thereto
View Patent ↗The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
1. A polypeptide comprising a mutant OspA fragment heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186), Lip-S2D1-S1D1 (SEQ ID NO: 192), Lip-S1D1-S2D4 (SEQ ID NO: 198), and Lip-S2D4-S1D1 (SEQ ID NO: 203).
2. A polypeptide consisting of a mutant OspA fragment heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO: 186), Lip-S2D1-S1D1 (SEQ ID NO: 192), Lip-S1D1-S2D4 (SEQ ID NO: 198), and Lip-S2D4-S1D1 (SEQ ID NO: 203).
3. A pharmaceutical composition comprising at least one of the polypeptides according to claim 1 and optionally a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition comprising Lip-S1D1-S2D1 (SEQ ID NO: 186), optionally, one or more additional mutant OspA fragment heterodimers, and optionally a pharmaceutically acceptable carrier or excipient.
5. The polypeptide according to claim 1 for use in a method for treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection.
6. The pharmaceutical composition according to claim 3 for use in a method for treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection.
7. A pharmaceutical composition comprising the polypeptide according to claim 2 , and optionally a pharmaceutically acceptable carrier or excipient.
8. The pharmaceutical composition according to claim 3 , wherein the pharmaceutical composition is a vaccine.
9. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition is a vaccine.
10. The polypeptide according to claim 2 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is B. burgdorferi s.s. or B. afzelii infection.
11. The pharmaceutical composition according to claim 7 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is B. burgdorferi s.s. or B. afzelii infection.
12. The pharmaceutical composition according to claim 4 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is B. burgdorferi s.s. or B. afzelii infection.